Screening of the use of benzodiazepines during COVID-19 pandemic in the general population

Abstract

Benzodiazepines have been commonly prescribed for the treatment of anxiety and insomnia in the last few decades. There has been a rising concern regarding safety of benzodiazepines due to overdose related deaths, addictions and cognitive side effects. COVID-19 pandemic is expected to cause a mental health crisis. Several studies have shown an increase in anxiety and insomnia. Тhe prescriptions of benzodiazepines could increase due to increase in anxiety and insomnia. The pandemic calls for a rapid adaptation of conventional medical practices to meet the evolving needs of such vulnerable patients. COVID-19 patients may frequently require treatment with psychotropic medications. This pandemic is leading to additional health problems such as stress, anxiety, depressive symptoms, insomnia, denial, anger and fear, globally. The COVID-19 pandemic is a challenge to humanity. It is not only a health crisis but also a social crisis. The life is unlikely to be the same after we come out of the pandemic. There will be changes at the level of individuals, families, communities, states, nations, international relationships, and the way all of us will deal with a range of human and environmental situations. Disasters are always associated with increased rates of emotional health needs from distress to specific disorders, such as posttraumatic stress disorder. Past experiences have shown psychosocial interventions, ranging from self‑care, psychological first aid, counseling, social support and formal psychiatric care can minimize the emotional health impact of disasters. These activities can be initiated by individuals and professionals. Keywords: coronavirus, COVID-19, mental health, benzodiazepines